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Purpose: To examine the validity of registration of hydatidiform mole (HM) in the Danish 
National Patient Registry (NPR), the Danish Cancer Registry (DCR), and the Danish Pathol-
ogy Registry (DPR).
Patients and methods: We selected women registered with a first-time HM code in NPR, 
DCR, and DPR from 1999 to 2009. We found most women registered in DPR. For a random 
sample of women registered in DPR, the coding was validated by comparing with the pathol-
ogy report. Completeness and positive predictive value (PPV) of registration with an HM code 
in NPR and DCR were calculated using DPR as the reference. Details of women registered in 
NPR or DCR, but not in DPR, were scrutinized.
Results: In NPR and DPR, 1,520 women were identified in total; 1,057 (70%) were found in 
both registries, 65 (4%) only in NPR, and 398 (26%) only in DPR. In DCR and DPR, 1,498 
women were identified in total; 1,174 (78%) in both registries, 47 (3%) only in DCR, and 277 
(19%) only in DPR. For 149/150 randomly selected women registered with an HM code in DPR 
(99%), the pathology report was consistent with the diagnosis of HM. Completeness of NPR 
was 73% (95% CI: 70%–75%) and PPV was 94% (95% CI: 93%–95%). Completeness of DCR 
was 72% (95% CI: 69%–75%) in 1999–2003 and 90% (95% CI: 87%–92%) in 2004–2009. 
PPV of DCR was 96% (95% CI: 95%–97%) throughout the period.
Conclusion: Validation of registry data is important before using these. For research on the 
number of HMs in Denmark, DPR is the most valid data source. NPR and DCR appear to be 
equally valid before 2004. However, for research after 2004, DCR should be preferred rather 
than NPR.
Keywords: epidemiology, completeness, positive predictive value, complete hydatidiform mole, 
partial hydatidiform mole, agreement
Introduction
Hydatidiform mole (HM) is an abnormal pregnancy and the most common form of 
gestational trophoblastic disease. HMs are characterized by vesicular swelling of the 
chorionic villi, hyperplasia of the trophoblastic layer, and absence or abnormal devel-
opment of the fetus. HMs can be classified into two types, complete hydatidiform 
mole (CHM) and partial hydatidiform mole (PHM).1 The incidences of HM reported 
in different parts of the world are highly varying. In Europe and North America, the 
reported HM incidences range from 66 to 121 per 100,000 pregnancies, while much 
higher incidences have been reported in Asia and the Middle East.2 The causes of the 
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varying incidences reported have not been established, but 
it has been suggested that diet and nutrition may contribute 
to the etiology.3 Comparing incidence rates of HM from 
different studies is difficult. The population at risk may be 
inadequately described, the methodological design varies, 
there may be differences in disease definition and changes 
in diagnostic methods over time.4–6 Previous studies have 
demonstrated underreporting of HMs to the Swedish Cancer 
Register with only very little improvement over time.7,8 In 
Denmark, women with an HM are registered in three gov-
ernmental registries: the Danish National Patient Registry 
(NPR),9 the Danish Cancer Registry (DCR),10 and the Danish 
Pathology Registry (DPR).11 The aim of this study was to 
examine the validity of the registration of HMs in the NPR, 
the DCR, and the DPR from 1999 to 2009.
Patients and methods
registries
The NPR is an electronic medical registry storing data of all 
patients discharged from Danish somatic hospitals nation-
wide since 1977.12 Data on outpatients have been registered 
since 1995. Standardized data from regional Patient Admin-
istrative Systems are submitted electronically to the NPR at 
least monthly, but in practice often weekly or daily.13 The 
information reported to the NPR includes administrative data 
and data on diagnoses, examinations, and treatments (http://
www.esundhed.dk/dokumentation/Registre/Sider/Register.
aspx). The 10th revision of the International Classification 
of Diseases (ICD10) has been used to classify diseases since 
1994.9
The DCR has recorded primary cases of cancer and 
related diseases (including HMs) on a nationwide basis since 
1943, and reporting has been mandatory since 1987. The 
information recorded in the DCR includes both personal and 
tumor characteristics (http://www.esundhed.dk/dokumenta-
tion/Registre/Sider/Register.aspx). In 2004, the DCR went 
through a process of modernization, which included elec-
tronic notifications from the NPR and an automated cancer 
logic algorithm based on ICD10 replacing former paper 
notifications from hospitals. Furthermore, data registered in 
the period 1978–2004 were re-coded using ICD10.14 Approxi-
mately, 80%–90% of the manual coding has been replaced 
by the automatic cancer logic.10 Reminders are regularly 
dispatched to the hospitals who fail to report.
Computer-based recording of pathology data began in 
Denmark in the 1970s. The DPR was established in 1997. 
Since 1999, reporting in the DPR automatically takes place 
through the Danish Pathology Data Bank (DPB), a  nationwide 
database, working as a routine online tool for all pathology 
departments in Denmark. For each specimen, patient data, date 
of registration, the requesting and investigating hospitals and 
departments, gross and microscopy descriptions, and diag-
noses are registered. Coding is performed using the  Danish 
modification of the Systemized Nomenclature of Medicine 
(SNOMED, http://www.patobank.dk/). The data quality is 
ensured by the approval of all diagnostic statements in the 
pathology report by a pathologist and a debugging system, 
which ensures that all statements are given at least one code 
for topography and one code for morphology. When a new 
pathology report is completed in the DPB, data are automati-
cally sent to the DPR, which is updated on a daily basis.11,15
Using the 10-digit civil personal registration number16,17 
assigned to all Danish citizens at birth or immigration since 
1968, unambiguous data linkage between the abovemen-
tioned registries is possible.
Identification of women
We initially retrieved data on all women registered with 
an HM code in the NPR, the DCR, and/or the DPR from 
1.1.1987 to 31.12.2010. In the NPR, the DCR, and the DPR, 
women were registered with their civil personal registration 
number, the date of registration, and an HM code, along with 
a number of other variables. It is possible for a woman to be 
registered with an HM code more than once in the NPR and 
the DPR, but a woman with an HM is registered only with her 
first HM in the DCR. To make the data sets comparable, we 
adjusted the data sets from the NPR and the DPR: a woman 
registered with an HM code more than once in a registry was 
included in the data set from that registry with the date of 
the first HM code only.
To validate the registration of women with an HM code 
in the NPR, the DCR, and the DPR in the period 1999–2009, 
we selected data on women registered with an HM code 
for the first time in the above data sets from 1.1.1999 to 
31.12.2009. The codes used for identification of the women 
with an HM in the various registries are listed in Table 1. In 
the DPR, code M91000 most likely was intended to indicate 
a woman diagnosed with a CHM. However, as no other code 
was available, M91000 may also have been used to indicate 
that the women had an “HM, not otherwise specified”. In the 
Danish SNOMED, the code ÆYYY00 is a moderator indicat-
ing “suspicion of ”. The code can be used as a supplement to 
the morphology codes.
A woman was classified as being registered identically in 
two registries, if she was registered in both registries and the 
difference between the two dates of registration in the two 
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registries was <6 months. Two and one women registered in 
1998 with an HM code in the NPR and the DCR, respectively, 
were included in the data sets from these registries, as these 
women were registered in the DPR in 1999, and there was 
<6 months between the two dates of registration. Likewise, 
one woman registered in both the NPR and the DCR in 2010 
was included in the data sets from these registries, as she was 
registered in the DPR in 2009 <6 months earlier (Figure 1).
Including women with their first HM code only could 
introduce errors. For instance, if a woman actually had had 
two HMs, and both HMs were coded as HMs in the DPR, 
whereas only the second HM was coded as an HM in the 
NPR, we would underestimate both completeness and posi-
tive predictive value (PPV) of the NPR relative to the DPR. 
To compensate for this, we next excluded women from the 
data sets from the NPR and the DPR, and the DCR and the 
DPR who had >6 months between the dates of registration 
in the two registries. This led to exclusion of three women 
from the data set from the NPR and the corresponding data set 
from the DPR, and seven women from the data set from the 
DCR and the corresponding data set from the DPR (Figure 1).
Women present in the data set from the NPR and/or the 
DCR, but not present in the data set from the DPR, were re-
searched in the DPR 4 years after the primary search, and the 
causes explaining the difference were categorized. Women 
present in the data set from the DPR, but not present in the data 
set from the NPR, were researched in the original data set from 
the NPR, to identify women excluded during the reduction of 
the data sets to include women with first-time HM codes only.
To evaluate the validity of the HM coding in the DPR, 
we checked the pathology report for 150 randomly selected 
women with an HM according to the SNOMED coding 
in the period from 1999 to 2009. The pathology reports 
were reviewed by two pathologists, with special interest in 
Table 1 Codes for hM in the DPr, the DCr, and the nPr in 1999–2009a
DPR (SNOMED) DCR (ICD10) NPR (ICD10)
Code Diagnosis Code Diagnosis Code Diagnosis
M91000 hydatidiform mole DO010 Complete hydatidiform mole DO010 Complete hydatidiform mole
DO019 hydatidiform mole, not 
otherwise specified
DO019 hydatidiform mole, not otherwise 
specified
M91030 Partial hydatidiform mole DO011 Partial hydatidiform mole DO011 Partial hydatidiform mole
ÆYYY00b a moderator indicating 
“suspicion of”
DO019a intrauterine hydatidiform mole
DO020B Extrauterine hydatidiform mole
Notes: aThe table also illustrates the corresponding hM codes for calculating agreement and kappa values for registration of morphologic subdiagnoses of hMs. bThe 
moderator code ÆYYY00 can be used as a supplement to the morphology code (M91000 or M91030).
Abbreviations: DCR, Danish Cancer Registry; DPR, Danish Pathology Registry; HM, hydatidiform mole; ICD10, 10th revision of the International Classification of Diseases; 
nPr, national Patient registry; snOMED, systemized nomenclature of Medicine.
 gynecological pathology (HL and AG). Based on the descrip-
tion in the pathology report, a conceptus was classified as an 
HM if the conclusion stated that the conceptus was an HM 
and/or if the report listed morphological findings diagnostic 
for an HM.18 Next, the conceptuses identified as HMs were 
categorized into four groups: CHM, PHM, HM-NOS and 
HM, subtype not specified. HMs for which the conclusion in 
the pathology report stated a CHM or PHM were classified 
as such. An HM for which the report stated that subtyping 
had not been possible, was classified as an HM-NOS. If 
there was no clear conclusion regarding the subtype of HM 
in the pathology report, the reviewing pathologists classified 
the subtype if possible using the histopathological features 
of HMs described by Sebire.18 The fourth group represents 
HMs, for which the text was not sufficiently informative 
for the reviewing pathologists to perform subtyping (HM, 
subtype not specified).
statistical analysis
As no pathology report can be signed out without registration 
in the DPR, the proportion of missing data in this registry is 
expected to be low.11 Concordantly, comparing registration 
in the NPR, the DCR, and the DPR, more women were reg-
istered in the DPR than in the NPR and the DCR (details are 
provided in the “Results” section). Although more accurate 
sonographic diagnoses, especially for CHMs, have been 
observed,19 histopathological examination of conceptuses 
remains the current gold standard for the identification of 
gestational trophoblastic diseases.20 Furthermore, 149/150 
women registered with an HM code in the DPR had an HM 
according to the pathology report (details are provided in the 
“Results” section). Therefore, we used data from the DPR 
as the reference standard calculating the completeness and 
PPV of data from the NPR and the DCR. The completeness 
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of the NPR and the DCR was calculated as the number of 
women registered with an HM code in the data set from the 
DPR, who were also found with an HM code in the data sets 
from the NPR and the DCR, respectively, divided by the total 
number of women registered with an HM code in the data 
set from the DPR. Likewise, the PPV was calculated as the 
proportion of women registered with an HM code in both of 
the data sets from the DPR and the NPR, or the DPR and the 
DCR, to the women registered with an HM code in the data 
set from the NPR or the DCR, respectively.
To determine the degree of consensus between the 
morphologic subdiagnoses of HMs registered in the NPR 
and the DPR, and the DCR and the DPR, respectively, the 
agreement and Cohen’s kappa values were calculated.21 
The codes for morphologic subdiagnoses accepted as cor-
responding in the three registries are shown in Table 1. 
Statistical analyses were performed with STATA software 
version 13 (StataCorp LLC. College Station, USA). The 
study was approved by the Danish Protections Agency (j. 
nr. 2014-41-3541).
Results
In the period 1.1.1999–31.12.2009, 1,520 women were reg-
istered for the first time with an HM code in the NPR and/
or registered for the first time in the DPR with an HM code. 
One thousand fifty-seven women (70%) were registered in 
both registries, 65 women (4%) were registered in the NPR 
only, and 398 women (26%) were registered in the DPR only 
(Table 2). Likewise, in the period 1.1.1999–31.12.2009, 1,498 
women were registered for the first time in the DCR with an 
HM code and/or registered for the first time in the DPR with 
an HM code. One thousand one hundred seventy-four women 
(78%) were registered in both registries, 47 (3%) were regis-
tered only in the DCR, and 277 (19%) were registered only 
in the DPR (Table 3). Thus, the DPR was the registry with 
the highest number of women registered with an HM code.
In the DPR, the moderator code ÆYYY00 indicating 
“suspicion of ” had been added to the morphology code for 
15% of the women (Table 4). No significant difference was 
observed regarding the use of the moderator code in the 
period before and after 2004 (data not shown).
For 150 randomly selected women, 149 registered with 
an HM code in the DPR had an HM according to the pathol-
ogy report (Table 5). For one woman, there was discrepancy 
between the report and the coding. The conceptus was 
initially described as a suspected PHM and coded M91030 
+ ÆYYY00. Following flow cytometry, the pathologist con-
cluded in the pathology report that the conceptus was not an 
Figure 1 Data retrieval of women registered with an hM code in the nPr, the DCr, and the DPr. Two different data sets from DPr were created. aFor comparing with the 
data set from the nPr, three women registered in the nPr and the DPr with >6 months between the dates of registration were excluded. bFor comparing with the DCr, 
seven women registered in the DCr and the DPr with >6 months between the dates of registration were excluded.
Abbreviations: DCr, Danish Cancer registry; DPr, Danish Pathology registry; hM, hydatidiform mole; nPr, national Patient registry.
NPR
Women registered with a first-time HM code from 1.1.1987 to 31.12.2010.
DCR DPR
2,837 2,004 2,430
Exclusion of women registered before 1.1.1999 or after 31.12.2009.
Inclusion of women registered in the NPR or the DCR in 1998 <6 months before being registered in the DPR,
and of women registered in NPR or the DCR in 2010 <6 months after being registered in the DPR.
Exclusion of women registered in both the NPR and the DPR, and the DCR and the DPR, if there were >6 months
between the registration in the NPR and the DPR and the DCR and the DPR, respectively.
1,122 1,226
1,125 1,228
1,122 1,221 1,455 (NPR)a
1,451 (DCR)b
1,458
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HM, but the coding remained unchanged. For 76/77 women 
registered with the code M91030, the pathology report 
stated that they had a partial hydatidiform mole. Forty-six 
of 73 women registered with the code M91000 had a CHM 
according to the pathology report.
Using the data set from the DPR as the reference standard, 
the completeness of the NPR from 1.1.1999 to 31.12.2009 
was 73% (95% CI: 70%–75%) and the PPV was 94% 
(95% CI: 93%–95%; Table 6). There were no significant 
Table 2 Number of women with a first-time hydatidiform mole code in the NPR and/or the DPR in 1999–2009
Data set from DPRa Women registered in Total, n
Both NPR and DPR, n (%) Only NPR, n (%) Only DPR, n (%)
all 1,057 (70) 65 (4) 398 (26) 1,520
Without ÆYYY00 954 (68) 168 (12) 286 (20) 1,408
Notes: aall: Data set including women registered with the snOMED code M91000 (hydatidiform mole) or M91030 (partial hydatidiform mole), with or without ÆYYY00 
(suspicion of). Without ÆYYY00: Data set including only women registered with the snOMED code M91000 or M91030, without ÆYYY00.
Abbreviations: DPr, Danish Pathology registry; nPr, national Patient registry; snOMED, systemized nomenclature of Medicine.
Table 3 Number of women with a first-time hydatidiform mole code in the DCR and/or the DPR in 1999–2009
Data set from DPRa Women registered in Total, n
Both DCR and DPR, n (%) Only DCR, n (%) Only DPR, n (%)
all 1,174 (78) 47 (3) 277 (19) 1,498
Without ÆYYY00 1,088 (79) 133 (10) 148 (11) 1,369
Notes: aall: Data set including women registered with the snOMED code M91000 (hydatidiform mole) or M91030 (partial hydatidiform mole), with or without ÆYYY00 
(suspicion of). Without ÆYYY00: Data set including only women registered with the snOMED code M91000 or M91030, without ÆYYY00.
Abbreviations: DCr, Danish Cancer registry; DPr, Danish Pathology registry; snOMED, systemized nomenclature of Medicine.
Table 4 Number of women registered with a first-time hydatidiform mole code in the Danish Pathology Registry in 1999–2009a
SNOMED code M91000 SNOMED code M91030 Total, n
Without ÆYYY00,
n (%)
With ÆYYY00,
n (%)
All,
n (%)
Without ÆYYY00,
n (%)
With ÆYYY00,
n (%)
All,
n (%)
552 (85) 99 (15) 651 (100) 691 (86) 116 (14) 807 (100) 1,458
Notes: aThe data set presented here is larger than the data sets presented in Tables 2 and 3, as three and seven women, respectively, were excluded from the latter data sets 
because the dates of registration in two registries differed >6 months (details are provided in the “Patients and methods” section). The code M91000 represents hydatidiform 
mole, M91030 represents partial hydatidiform mole, and ÆYYY00 represents a moderator indicating “suspicion of”.
Abbreviation: snOMED, systemized nomenclature of Medicine.
Table 5 Concordance between the description in the pathology report and the snOMED code in 150 randomly selected women 
registered with a first-time HM code in Danish Pathology Registry in 1999–2009
Code Information in the pathology report
Not 
mole
HM, subtypea Total, subtype 
specified
HM, subtype not 
specifiedb
Total, subtype specified  
or not specifiedCHM PHM HM- NOS
M91000 0 46 11 8 65 8 73
M91030 1 0 76 0 77 0 77
Total 1 46 87 8 142 8 150
Notes: aThe HMs were categorized according to the pathology report into CHMs, PHMs, or HM-NOS. bHMs for which the pathology report was not sufficiently informative 
to the reviewing pathologists to identify the subtype.
Abbreviations: CHMs, complete hydatidiform moles; HM, hydatidiform mole; HM-NOS, HMs for which subtyping was not possible; PHMs, partial hydatidiform moles; 
snOMED, systemized nomenclature of Medicine.
 differences between the completeness and PPV for the peri-
ods 1.1.1999–31.12.2003 and 1.1.2004–31.12.2009 (data 
not shown). When excluding women registered with an HM 
code with the moderator code ÆYYY00 from the data set 
from the DPR, the completeness of NPR improved to 77% 
(95% CI: 75%–79%), while the PPV lowered to 85% (95% 
CI: 83%–87%).
In the period 1.1.1999–31.12.2003, the completeness of 
the DCR relative to the DPR was 72% (95% CI: 69%–75%). 
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There was an improvement in the completeness to 90% (95% 
CI: 87%–92%) for the period 1.1.2004–31.12.2009. The PPV 
was 96% (95% CI: 95%–97%), with no significant differ-
ence between the periods before and after 1.1.2004 (Table 6). 
When excluding women registered with HMs with the mod-
erator code ÆYYY00 in the DPR, the completeness of the 
DCR improved to 98% (95% CI 97%–99%) for the period 
1.1.2004–31.12.2009, and the PPV for this period lowered 
to 89% (95% CI: 86%–91%).
A total of 76 women were identified with an HM code 
in the NPR and/or the DCR but not in the DPR (Table 7). 
Scrutinizing the data for these, we identified 33 women for 
whom the data in the DPR indicated that the women had had 
a nonmolar conceptus in the relevant period, and nine women 
for whom the discrepancy could be explained by the HM in 
question not being the first HM of the patient, the registrations 
in two registers being made before and after the start of the 
study period, respectively, or the diagnosis being made in a 
non-Danish citizen. However, for 18 women, an HM code 
was apparently truly missing in our first data set: 11 women 
apparently had been diagnosed with an HM in the period, 
however, this was only registered after we retrieved the data 
set and 7 women had been diagnosed with an HM according 
to the pathology report, but an unspecific (n=6) or incorrect 
(n=1) code had been chosen. For 16 women, no relevant 
data were available in the DPR. Based on these observa-
tions, the completeness of the DPR would be between 1,458/
(1,458+18)=98.8% and 1,458/(1,458+34)=97.7%. No women 
were “missing” in the NPR data set due to HMs diagnosed 
before the study period (data not shown).
Of the 1,057 women registered for the first time with 
an HM code in both the NPR and the DPR, 1,046 women 
were registered with codes indicating morphologic subtypes 
Table 6 Completeness and PPV for registration of a woman with a hydatidiform mole in the nPr and the DCr using registration in 
the DPr as reference standard
Registry Period Data from DPRa Completeness (95% CI), % PPV (95% CI), % nb
nPr 1999–2009 all 73 (70–75) 94 (93–95) 1,520
Without ÆYYY00 77 (75–79) 85 (83–87) 1,408
DCr 1999–2009 all 81 (79–83) 96 (95–97) 1,498
Without ÆYYY00 88 (86–90) 89 (87–91) 1,369
1999–2003 all 72 (69–75) 95 (93–97) 770
Without ÆYYY00 79 (75–82) 90 (87–92) 702
2004–2009 all 90 (87–92) 97 (95–98) 728
Without ÆYYY00 98 (97–99) 89 (86–91) 667
Notes: aall: Data set including women registered with the snOMED code M91000 (hydatidiform mole) or M91030 (partial hydatidiform mole), with or without ÆYYY00 
(suspicion of). Without ÆYYY00: Data set including only women registered with the snOMED code M91000 or M91030, without ÆYYY00. bThe number of women included 
in the data set from the registry indicated or in the data set from the DPr or both, for the period indicated.
Abbreviations: DCr, Danish Cancer registry; DPr, Danish Pathology registry; nPr, national Patient registry; PPV, positive predictive value; snOMED, systemized 
nomenclature of Medicine.
of HM that could be related (11 women were excluded, 
as they were registered in the NPR with the ICD10 codes 
DO019A or DO020B, which could not be related to the 
codes of HM in the DPR; Table 1). The agreement between 
the subtypes registered in the NPR and the DPR was 84% 
(95% CI: 82%–86%), and the kappa value was 0.68 (95% CI: 
0.64–0.73) with no significant difference between the periods 
1.1.1999–31.12.2003 and 1.1.2004–31.12.2009 (Table 8). For 
the 1,174 women registered for the first time with an HM code 
in both the DCR and the DPR, the agreement between the 
morphologic subtypes registered increased from 71% (95% 
CI: 67%–75%) in the period 1.1.1999–31.12.2003 to 77% 
(95% CI: 73%–80%) in 1.1.2004–31.12.2009 (P=0.02). In 
the same period, the kappa value increased from 0.45 (95% 
CI: 0.38–0.51) to 0.54 (95% CI: 0.47–0.60; Table 9).
Discussion
In this study, we examined the validity of registration of 
women with HMs in three national Danish registries, the 
NPR, the DCR, and the DPR.
The strength of our study is that the health care system 
in Denmark ensures equal access to free health care to all 
residents, and clinicians in the public health care system 
are obliged to register patients in a number of nationwide 
databases. Thus, we were able to compare the registration of 
women with HMs in not only two, but in three nation-wide 
health registries. Furthermore, we were able to link data using 
the Danish civil personal registration number that uniquely 
identifies every Danish citizen.
A limitation to our study is that we reduced the data sets 
from the NPR and the DPR to women with a first-time HM 
code, and that we further excluded women registered for the 
first time with an HM code in the NPR and the DPR, or in 
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the DCR and the DPR on dates that were >6 months apart, 
to reduce errors caused by the reduction of the data sets to 
women with a first-time HM code. However, this affected 
only three and seven women, respectively.
We found indications that the DPR was the most valid 
register. The DPR had most women registered with an HM 
code, and the concordance between the description in the 
pathology report and the codes in the DPR was very good. 
Table 7 Characterization of women registered with an hM code in the nPr (n=65) and the DCr (n=47), but not registered with an 
hM code in the DPr
Characteristics Number of women identified in the 
registry indicated, but not in the DPR
Both NPR  
and DCR
Only
NPR
Only
DCR
Total
The woman was not registered with a conception in the DPr in the relevant period 10 2 4 16
The woman was not registered with an hM code in the DPr when the original data set 
was retrieved, but was identified when the DPR was researcheda
4 4 3 11
The woman was registered with a conception in the DPR, but the morphological findings 
were not diagnostic for hM according to the pathology report
14 16 3 33b
The woman was registered in the DPr with a code indicating a pregnancy, but not 
specifying that this was an hM, whereas the description in the pathology report was 
consistent with a diagnosis of hM
7c 0 0 7
Other causes 1d 7e 1f 9
Total 36 29 11 76
Notes: aThe DPr was researched 4 years after the original search. bFor 6/33 women, there was some discussion regarding trophoblastic diseases in the pathology 
report. cFor 6/7 women, the coding was made by the same pathologist, who used the code for “abnormal pregnancy product” even though the pathologist used the term 
“hydatidiform mole” in the description in the pathology report. dThe woman was diagnosed with an hM outside Denmark and apparently subsequently treated and registered 
in both the nPr and the DCr in Denmark. eOne woman was diagnosed with an hM within the relevant period, but was excluded from our DPr data set as the patient had 
a previous mole; two women were registered in the DPr in late December 1998 and therefore not included in our DPr data set, but registered in the nPr between January 
and February 1999; four women were registered with a temporary CPr number in the nPr, but they were not registered in the DPr. fThe woman was diagnosed with an 
hM within the relevant period, but was excluded from our DPr data set as the patient had a previous mole.
Abbreviations: DCr, Danish Cancer registry; DPr, Danish Pathology registry; hM, hydatidiform mole; nPr, national Patient registry.
Table 8 agreement and kappa values for morphologic 
subdiagnoses of hydatidiform mole registered in the Danish 
national Patient registry and the Danish Pathology registry
Perioda Agreement 95% CI Kappa 95% CI
1999–2009 84% 82%–86% 0.68 0.64–0.73
1999–2003 83% 80%–86% 0.66 0.60–0.72
2004–2009 85% 82%–88% 0.71 0.65–0.77
Notes: aPeriod: 1.1.1999–31.12.2009, 1.1.1999–31.12.2003, and 1.1.2004–
31.12.2009.
Table 9 agreement and kappa values for morphologic 
subdiagnoses of hydatidiform mole registered in the Danish 
Cancer registry and the Danish Pathology registry
Perioda Agreement 95% CI Kappa 95% CI
1999–2009 74% 72%–77% 0.50 0.45–0.54
1999–2003 71% 67%–75% 0.45 0.38–0.51
2004–2009 77% 73%–80%b 0.54 0.47–0.60
Notes: aPeriod: 1.1.1999–31.12.2009, 1.1.1999–31.12.2003, and 1.1.2004–
31.12.2009. bP=0.02.
This was not surprising because HM is a morphological 
diagnosis that in principle should be made by the pathologist, 
and registration in the DPR is linked to signing out of the 
pathology report. Nevertheless, we disclosed some women 
registered with an HM in the NPR or the DCR, but not in the 
DPR. Furthermore, we cannot exclude that some women were 
diagnosed with an HM and not registered with an HM code 
in any of the three registries. However, a substantial fraction 
of the women registered with an HM code in the NPR and/
or the DCR but not in the DPR were registered in the DPR 
in the relevant period with a non-HM code, suggesting that 
these women were erroneously registered with an HM code 
in the NPR or the DCR. Furthermore, as almost 99% of the 
women registered with an HM code in the NPR and/or the 
DPR, and almost 99% of the women registered with an HM 
code in the DCR and/or the DPR were actually registered 
with an HM code in the DPR, the frequency of missing 
registrations in the DPR is likely very small.
The finding that almost half of the women “missing” in 
the DPR actually were diagnosed and registered in the DPR 
with morphological findings in a conceptus not diagnostic 
for HM may be explained by coding in the NPR and the DCR 
before receiving the final pathology report. The miscoding 
caused by one pathologist repeatedly using the less-specific 
code “abnormal pregnancy product”, even though the text in 
the pathology report was consistent with a diagnosis of HM, 
illustrates the importance of using national coding guidelines.
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In the period 1999–2003, both the NPR and the DCR 
demonstrated a completeness of 72% compared with the 
DPR. A comparable underreporting of 20%–25% in the 
Swedish Cancer registry with little improvement over time, 
has been documented for the periods 1971–19868 and 
1973–2004,7 although reporting to the cancer registry was 
mandatory in Sweden. As molar diseases are relatively rare 
and diagnosed in both specialized and in nonspecialized 
hospitals, the observed underreporting may be explained by 
lack of knowledge that HMs should be registered in the same 
registry as malignant diseases. Also, doctors at nonspecial-
ized hospitals who see only few cases of hydatidiform mole 
during their professional life, may have a tendency to choose 
a wrong or less-specific code. The marked improvement in 
completeness and agreement for morphological subdiagnoses 
in the DCR compared with the DPR after 2003, corresponds 
well with the improved method of registration in the DCR 
that is used since 2004.
The agreement and kappa values for registration of 
morphologic subdiagnoses of HM in the NPR relative to 
the DPR were higher than the agreement and kappa values 
for the DCR relative to the DPR throughout the period. This 
was unexpected, as since 2004 most of the data in the DCR 
originate from the NPR. However, the higher agreement for 
the NPR may be related to the lower completeness of the 
NPR – possibly a lower proportion of women diagnosed with 
diagnostically difficult cases of HM are registered in the NPR.
As PHMs can be difficult to separate morphologically 
and immunohistochemically from hydropic abortions,22,23 
one could have expected that the moderator ÆYYY00 indi-
cating some uncertainty regarding the diagnosis of HM, had 
been used more often for PHMs compared with CHMs. An 
increased use over time could have also been expected, due 
to the evacuation at earlier gestational ages with the advent 
of more sensitive ultrasound scanners over time. When an 
HM is terminated early, both the sonographic findings20 and 
the histopathological findings are more discrete,24,25 causing 
difficulties in diagnosing and subtyping HMs morphologi-
cally. On the other hand, one could also imagine a diminished 
use of the moderator code due to increased use of various 
ancillary techniques like immunohistochemical analyses and 
molecular genotyping.26,27 In our study, the moderator was 
added to the first-time HM code for 15% of the women in the 
DPR, and there was no significant difference regarding the 
morphological subdiagnosis of mole or registration before 
and after 2004. Others also use diagnoses of conceptuses 
suspected of HMs that cannot be classified unequivocally. 
In one study conceptuses suspected of PHM, but with villus 
morphology insufficient for a definitive diagnosis of PHM, 
were classified as either “morphology abnormal, favor PHM” 
or “morphology abnormal, probable nonmolar, PHM not 
excluded”.28 Thus, there is a continuing need for categories 
for classifying “inconclusive” and “suspected cases”. The 
observation that disregarding women registered with the 
moderator code ÆYYY00 in the DPR caused an increased 
completeness and a reduced PPV of registration in the NPR 
and DCR indicates that some of the conceptuses classified 
by the pathologist as a suspected HM were regarded by 
the clinicians to be HMs whereas others were regarded to 
be nonmolar conceptuses. Understanding the meaning of 
the moderator code in the SNOMED coding system, the 
researcher can decide if it is most informative to include 
or exclude women registered with this code in the DPR in 
a given study.
In this study, data retrieval from the DPR revealed some 
challenges in the Danish SNOMED regarding the morphol-
ogy code M91000 in the period examined. This code indicates 
that the women were diagnosed with an HM. Since the code 
M91030 indicates that the women were diagnosed with a 
PHM, one could assume the code M91000 was intended 
for women with CHMs. However, an HM, not otherwise 
specified, could also correctly have been encoded M91000. 
Thus, we do not know which of the women with this code 
had a CHM, and which had an HM that was not (or could 
not be) specified.
A good coding system should allow classification in 
exhaustive and mutually exclusive categories. We only dis-
closed that the codes for the morphological subdiagnoses in 
the DPR were not mutually exclusive during this study almost 
25 years after the codes had been introduced, illustrating that 
the quality of registries can benefit from the use of the data. 
In January 2014, the codes for HM in the DPR were adjusted 
by introducing specific morphology codes for “CHM” and 
“HM, not otherwise specified”.21 Thus, it would be relevant 
to repeat the validation study in 5–10 years.
Conclusion
For studying frequencies of HMs in the period 1999–2009, 
the DPR appears to be the most valid source. For a given 
study, one may wish to include or exclude women diagnosed 
with a suspected HM. The NPR and the DCR appear to be 
equally valid relative to the DPR before 2004. From 2004 
onward, the completeness and PPV for the DCR were higher 
than for the NPR.
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